Tag Archives: treating

Breast cancer treatment

Banner MDA engaged in cutting-edge study

A cutting-edge research study at Banner MD Anderson Cancer Center is testing the safety and effectiveness of a new investigational drug that, when combined with chemotherapy, may make a major difference in treating breast cancer in patients who carry harmful mutations on either the BRCA1 or BRCA2 genes.

The Brocade Study will enroll patients with hereditary breast cancer that is metastatic, meaning it has spread to other parts of the body, or locally recurrent, meaning it has come back in the same original area. These patients also have mutations in the BRCA1 or BRCA2 genes, similar to the kind that actress Angelina Jolie inherited. The study is examining the results of the oral drug Veliparib when taken in combination with chemotherapy treatments.

“These breast cancers can be very difficult to treat with traditional chemotherapy regimens. If Veliparib is found to add to the effectiveness of chemotherapy, it would give patients with BRCA mutations and metastatic breast cancer a new option for therapy,” said Mary Cianfrocca, MD, director of the Breast Cancer Program and medical director of the Clinical Cancer Genetics Program at Banner MD Anderson. Dr Cianfrocca is also the principal investigator for the Brocade Study at Banner MD Anderson.

Veliparib is designed to prevent the cancer cell from repairing itself by blocking a protein called PARP, possibly making the cell more susceptible to anti-cancer drugs. Banner MD Anderson is the only health care facility in Arizona which is offering the study. To learn more about the BROCADE study call 480-256-3420 or visit, www.brocadestudy.com.

Banner MD Anderson, located on the Banner Gateway campus, delivers cancer care to patients in Arizona through the collaboration of Banner Health and The University of Texas MD Anderson Cancer Center. Banner MD Anderson offers focused disease-specific expertise in the medical, radiation and surgical management of the cancer patient. The center uses an evidence-based, multidisciplinary approach to patient care, and provides access to clinical trials and new investigative therapies. Banner MD Anderson also offers state-of-the-art technology for diagnosing, staging and treating all types of cancer. For more information, visit www.BannerMDAnderson.com.

medical.research

TGen, Ventana announce research collaboration

The Translational Genomics Research Institute (TGen) and Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced a collaborative research agreement to discover and develop diagnostic markers for treating cancer.

The two Arizona-based institutions will leverage each other’s expertise in discovery and diagnostic product development, bringing innovative cancer diagnostic tests to patients.

The first project under the umbrella research agreement will focus on diagnostic, prognostic and drug biomarkers for pancreatic cancer, the fourth leading cause of death from cancer in the United States. This year, an estimated 45,000 people will be diagnosed and more than 38,000 patients will die from the disease. Worldwide, more than 213,000 are diagnosed with pancreatic cancer each year, and the numbers are growing. Fewer than 1 in 4 pancreatic cancer patients survive more than a year, and fewer than 6 percent survive more than five years – the worst survival rate of any cancer.

This dismal picture of pancreatic cancer is mainly due to the lack of tools for early detection and the ineffectiveness of current therapeutics. This is why new diagnostic markers and more efficacious therapies are desperately needed.

“TGen is on the cutting edge of translational research, where investigators discover the genetic components of disease,” says Jeffrey Trent, Ph.D., President and Research Director of TGen. “Our goal is to rapidly translate basic research findings into actionable targets. Partnering with Ventana we hope will accelerate our goal to deliver meaningful discoveries to cancer patients today.”

“When a patient is faced with cancer, getting an accurate diagnosis quickly is the most important part of their treatment,” says Ventana President and CEO Mara G. Aspinall. “As the global leader in tissue-based cancer diagnostics, our strength is moving research into the clinic in order to improve the lives of all patients afflicted with cancer. We are thrilled to be able to pursue this with a partner right in our Arizona backyard.”